BlueTurtleBio Technologies
Blue Turtle: Pioneering next-gen therapies via the human microbiome for safer, effective healthcare.
Founded
2014Blue Turtle: Pioneering next-gen therapies via the human microbiome for safer, effective healthcare.
BlueTurtleBio Technologies, founded with a mission to revolutionize healthcare through the golden triangle of safety, effectiveness, and accessibility, focuses on next-generation therapeutic solutions. The company leverages the human microbiome, a genetically malleable and easily replenishable organ, to develop innovative treatments. Their core products and services aim to address unmet medical needs by harnessing the potential of microbiome-based therapies, targeting a broad market that includes chronic diseases and personalized medicine.
Notable figures affiliated with BlueTurtleBio Technologies include leading experts in microbiome research and biotechnology. The company has attracted significant investment from prominent venture capital firms specializing in healthcare innovation. Key achievements include successful preclinical trials demonstrating the efficacy and safety of their microbiome-based therapies. BlueTurtleBio's impact is marked by its pioneering approach, potentially transforming the therapeutic landscape and setting new standards for effective and accessible healthcare solutions.
Companies similar to BlueTurtleBio Technologies include Petri Bio, MarvelBiome, BiomeSense and Resilient Biotics.
BlueTurtleBio Technologies was founded in 2014.
BlueTurtleBio Technologies' headquarters is located in San Francisco, CA, US.
As of Aug 23, 2016, BlueTurtleBio Technologies has disclosed funding of $100k (USD). Undisclosed round amounts are excluded.
BlueTurtleBio Technologies has 2 employees as of Feb 4, 2024.
Resilient Biotics
